Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NRX Pharmaceuticals, Inc. (NRXP)
|
Add to portfolio |
|
|
|
| Price: |
$4.71
| | Metrics |
| OS: |
81.7
|
M
| |
|
|
| Market cap: |
$385
|
M
| |
|
|
|
Net cash:
|
$15
|
M
| |
$0.18
|
per share
|
|
EV:
|
$370
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($36.6)
|
M
| |
|
|
|
EBIT
|
($36.7)
|
M
| |
|
|
| EPS |
($0.58)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative | | | 0.9 | 0.7 | 1.0 |
| Research and development | 17.0 | 20.3 | | | |
| General and administrative | 27.3 | 74.9 | | | |
| EBIT | -44.3 | -115.8 | -0.9 | -0.7 | -1.0 |
| Pre-tax income | -39.8 | -93.1 | -0.4 | 0.5 | 0.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 17.1% | 19.8% |
| Net income | -39.8 | -348.9 | -0.4 | 0.4 | 0.1 |
| |
| Diluted EPS | ($0.60) | ($7.44) | ($0.13) | $0.06 | $0.03 |
| Shares outstanding (diluted) | 65.8 | 46.9 | 3.3 | 7.3 | 2.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|